Loading organizations...
§ Private Profile · Philadelphia, PA, USA
Regenerative medicine company developing implantable biofabricated neural pathways to restore brain circuitry for neurological disorders.
Innervace is a Philadelphia, Pennsylvania-based biotechnology company developing implantable biofabricated neural pathways to restore damaged brain circuitry lost due to degeneration or injury. Its lead program focuses on reconstructing the nigrostriatal pathway for Parkinson's disease patients using pre-formed, anatomically-inspired tissue scaffolds with dopamine neurons, with potential applications for other neurological conditions. The company has raised approximately $49.99 million in total funding, including a Series A round led by Deerfield Management, and employs around 40 individuals. Notable investors include Deerfield Management, IP Group, Penn Medicine, and WARF Ventures, with Nader Halim, PhD, serving as CEO. Innervace was founded in 2020 by D. Kacy Cullen, PhD, and Douglas Smith, MD. Its business model centers on venture-funded biotech startup, raises capital through equity financing rounds to develop therapies.
Innervace has raised $40.0M across 1 funding round.
Innervace has raised $40.0M in total across 1 funding round.
Innervace has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in September 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 8, 2022 | $40M Series A | David Greenwald | BioAdvance, Penn Medicine, Warf Ventures | Announced |
Innervace has raised $40.0M in total across 1 funding round.
Innervace's investors include David Greenwald, BioAdvance, Penn Medicine, WARF Ventures.